Lymphoma, Low-Grade
15
0
0
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
20.0%
3 terminated out of 15 trials
75.0%
-11.5% vs benchmark
27%
4 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
FCM Versus R-FCM Followed by R-Maintenance or Observation Only
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Tandem Auto-Allo Transplant for Lymphoma
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Treatment of Localized Low Grade Lymphomas
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma